2023
DOI: 10.3390/pr11030889
|View full text |Cite
|
Sign up to set email alerts
|

Production of High-Value Proteins under Stringent Cost Constraints—The Case of Hollow Fiber Technology for Cell Culture

Abstract: For decades, the benefits of utilizing hollow fiber bioreactors for continuous cell culture to produce monoclonal antibodies have been widely recognized. However, the suitability of this technology for laboratories or centers with limited resources and expertise seeking to expand their production capacity is uncertain, mainly due to unknown cost-effectiveness. In this study, a hollow fiber bioreactor with a 4.7-mL culture volume was used to culture a hybridoma clone producing immunoglobulin G antibody specific… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 27 publications
0
1
0
Order By: Relevance
“…This unique construction and operation allow for the production of a large cell mass and high number of EVs [ 71 ]. The optimal production of a large cell mass in hollow-fiber bioreactors should take into account the quality control of parameters such as the pH; temperature; osmolarity; hypoxia; and nutrients added to the medium, including glucose and ion contents [ 72 ]. Therefore, the upscaling of hollow-fiber bioreactors from preclinical studies to manufacturing scale requires numerous iterative tests to keep the cell mass phenotype acceptable while producing EV batches on a large scale ( Supplementary Figure S1 ).…”
Section: Extracellular Vesicles Loaded With Diagnostic and Therapeuti...mentioning
confidence: 99%
“…This unique construction and operation allow for the production of a large cell mass and high number of EVs [ 71 ]. The optimal production of a large cell mass in hollow-fiber bioreactors should take into account the quality control of parameters such as the pH; temperature; osmolarity; hypoxia; and nutrients added to the medium, including glucose and ion contents [ 72 ]. Therefore, the upscaling of hollow-fiber bioreactors from preclinical studies to manufacturing scale requires numerous iterative tests to keep the cell mass phenotype acceptable while producing EV batches on a large scale ( Supplementary Figure S1 ).…”
Section: Extracellular Vesicles Loaded With Diagnostic and Therapeuti...mentioning
confidence: 99%